MCM3AP-AS1-knockdown weakens CDDP resistance in GC cells. (A) The IC50 was tested in NCI-N87, NCI-N87/CDDP, AGS and AGS/CDDP. (B) MCM3AP-AS1 expression in GC cells and CDDP-resistant GC cells was measured by RT-qPCR. (C) The knockdown efficiency of MCM3AP-AS1 in NCI-N87/CDDP and AGS/CDDP cells was assessed by RT-qPCR. (D) Migratory (magnification, ×200) and (E) invasive abilities (magnification, ×200) of CDDP-resistant GC cells were detected after repressing MCM3AP-AS1 by wound healing and Transwell assays, respectively. (F) Cell viability of NCI-N87/CDDP and AGS/CDDP cells was measured after repressing MCM3AP-AS1 by Cell Counting Kit-8 assay. (G) The IC50 of NCI-N87/CDDP and AGS/CDDP was tested after repressing MCM3AP-AS1 by drug-sensitivity assay. *P<0.05 vs. AGS, NCI-N87 or shNC. MCM3AP-AS1, MCM3AP antisense RNA 1; CDDP, cisplatin; GC, gastric cancer; RT-qPCR, reverse transcription-quantitative PCR; sh, short hairpin RNA; NC, negative control; OD, optical density.